Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Pahl, Jens H ^a   Kwappenberg, Kitty M ^a   Varypataki, Eleni M ^b   Santos, Susy J ^a   Kuijjer, Marieke L ^a   Mohamed, Susan ^a   Wijnen, Juul T ^a   Van Tol, Maarten J ^a   Cleton Jansen, Anne Marie ^a   Egeler, R Maarten ^c   Jiskoot, Wim ^b   Lankester, Arjan C ^a   Schilham, Marco W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cetuximab; IFN ; Macrophages; Muramyl tripeptide; Osteosarcoma

Indexed keywords

CD86 ANTIGEN; CETUXIMAB; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MIFAMURTIDE; MURAMYL TRIPEPTIDE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL CELL WALL; CANCER INHIBITION; CELL PHAGOCYTOSIS; COCULTURE; CONTROLLED STUDY; DRUG CONJUGATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; M1 MACROPHAGE; M2 MACROPHAGE; MACROPHAGE; MACROPHAGE ACTIVATION; OSTEOSARCOMA CELL; PRIORITY JOURNAL; UPREGULATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; LIPOSOMES; MACROPHAGES; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES;

EID: 84899117283     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-27     Document Type: Article

References (54)

1. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, J Clin Oncol 2008 26 633 638 10.1200/JCO.2008.14.0095 18235123
2. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J, J Exp Clin Cancer Res 2014 33 12 10.1186/1756-9966-33-12 24468065
3. New molecular insights into osteosarcoma targeted therapy. Yang J, Zhang W, Curr Opin Oncol 2013 25 398 406 10.1097/CCO.0b013e3283622c1b 23666471
4. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Buddingh EP, Kuijjer ML, Duim RA, Burger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PCW, Lankester AC, Cleton-Jansen AM, Clin Cancer Res 2011 17 2110 2119 10.1158/1078-0432.CCR-10-2047 21372215
5. The macrophage as an effector cell. Nathan CF, Murray HW, Cohn ZA, N Engl J Med 1980 303 622 626 10.1056/NEJM198009113031106 6447249
6. Macrophage activity and clinical immunology. Origin and kinetics of mononuclear phagocytes. van Furth R, Ann N Y Acad Sci 1976 278 161 175 10.1111/j.1749-6632.1976.tb47027.x 786119
7. Macrophage biology in development, homeostasis and disease. Wynn TA, Chawla A, Pollard JW, Nature 2013 496 445 455 10.1038/nature12034 23619691
8. Exploring the full spectrum of macrophage activation. Mosser DM, Edwards JP, Nat Rev Immunol 2008 8 958 969 10.1038/nri2448 19029990
9. Macrophage diversity in renal injury and repair. Ricardo SD, van GH, Eddy AA, J Clin Invest 2008 118 3522 3530 10.1172/JCI36150 18982158
10. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Sica A, Schioppa T, Mantovani A, Allavena P, Eur J Cancer 2006 42 717 727 10.1016/j.ejca.2006.01.003 16520032
11. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW, Nature 2011 475 222 225 10.1038/nature10138 21654748
12. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ, Lab Invest 1992 67 166 174 1501443
13. Differential macrophage programming in the tumor microenvironment. Ruffell B, Affara NI, Coussens LM, Trends Immunol 2012 33 119 126 10.1016/j.it.2011.12.001 22277903
14. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R, PLoS One 2012 7 47045 10.1371/journal.pone.0047045 23077543
15. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R, Clin Cancer Res 2007 13 1472 1479 10.1158/1078-0432.CCR- 06-2073 17332291
16. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazumder A, Cancer Res 1986 46 994 998 3000591
17. Activation of cytolytic activity in peripheral blood monocytes of renal cancer patients against non-cultured autologous tumor cells. Galligioni E, Quaia M, Spada A, Favaro D, Santarosa M, Talamini R, Monfardini S, Int J Cancer 1993 55 380 385 10.1002/ijc.2910550307 8375921
18. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ, Cancer Res 1983 43 2010 2014 6831430
19. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients. Sone S, Utsugi T, Tandon P, Yanagawa H, Okubo A, Ogura T, Cancer Immunol Immunother 1990 30 357 362 10.1007/BF01786885 2302725
20. In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Sone S, Fidler IJ, Cell Immunol 1981 57 42 50 10.1016/0008-8749(81)90118-0 7214534
21. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP, Curr Cancer Drug Targets 2006 6 123 133 10.2174/156800906776056473 16529542
22. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Kurzman ID, Shi F, Vail DM, MacEwen EG, Cancer Biother Radiopharm 1999 14 121 128 10.1089/cbr.1999.14. 121 10850295
23. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, Clin Cancer Res 1995 1 1595 1601 9815961
24. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, Conrad EU III, Nieder ML, Weiner MA, Wells RJ, Womer RB, Meyers PA, Cancer 2009 115 5339 5348 10.1002/cncr.24566 19637348
25. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de AE, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C, Genes Chromosomes Cancer 2010 49 40 51 10.1002/gcc.20717 19787792
26. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH, J Leukoc Biol 2006 79 285 293 16330536
27. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. Munn DH, Cheung NK, J Exp Med 1989 170 511 526 10.1084/jem.170.2.511 2526848
28. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J, J Immunol 2009 182 4415 4422 10.4049/jimmunol.0713732 19299742
29. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. Decker T, Lohmann-Matthes ML, Gifford GE, J Immunol 1987 138 957 962 3492537
30. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Oflazoglu E, Stone IJ, Brown L, Gordon KA, van RN, Jonas M, Law CL, Grewal IS, Gerber HP, Br J Cancer 2009 100 113 117 10.1038/sj.bjc.6604812 19066610
31. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Pahl JH, Ruslan SE, Buddingh EP, Santos SJ, Szuhai K, Serra M, Gelderblom H, Hogendoorn PC, Egeler RM, Schilham MW, Lankester AC, Clin Cancer Res 2012 18 432 441 10.1158/1078-0432.CCR-11-2277 22090361
32. II. Contribution to the Knowledge of Sarcoma. Coley WB, Ann Surg 1891 14 199 220 17859590
33. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Wiemann B, Starnes CO, Pharmacol Ther 1994 64 529 564 10.1016/0163-7258(94)90023-X 7724661
34. An endotoxin-induced serum factor that causes necrosis of tumors. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B, Proc Natl Acad Sci USA 1975 72 3666 3670 10.1073/pnas.72.9.3666 1103152
35. Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Merser C, Sinay P, Adam A, Biochem Biophys Res Commun 1975 66 1316 1322 10.1016/0006-291X(75)90503-3 1191296
36. Signal integration between IFNgamma and TLR signalling pathways in macrophages. Schroder K, Sweet MJ, Hume DA, Immunobiology 2006 211 511 524 10.1016/j.imbio.2006.05.007 16920490
37. IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2. Totemeyer S, Sheppard M, Lloyd A, Roper D, Dowson C, Underhill D, Murray P, Maskell D, Bryant C, J Immunol 2006 176 4804 4810 16585574
38. Synergism of recombinant human interferon gamma with liposome- encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes. Sone S, Tandon P, Utsugi T, Ogawara M, Shimizu E, Nii A, Ogura T, Int J Cancer 1986 38 495 500 10.1002/ijc.2910380407 3093390
39. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Girardin SE, Hugot JP, Sansonetti PJ, Trends Immunol 2003 24 652 658 10.1016/j.it.2003.10.007 14644139
40. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Dinney CP, Utsugi T, Fidler IJ, von Eschenbach AC, Killion JJ, Cancer Res 1992 52 1155 1161 1531322
41. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C, Bekker LG, Wood R, Harrison TS, AIDS 2012 26 1105 1113 10.1097/QAD.0b013e3283536a93 22421244
42. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ, Cancer Res 1986 46 5401 5405 3093063
43. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. Goldbach P, Dumont S, Kessler R, Poindron P, Stamm A, Am J Physiol 1996 270 429 L434 8638735
44. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, Uppaluri R, Andrews DM, Ngiow SF, Teng MW, Smyth MJ, Schreiber RD, Bui JD, J Exp Med 2012 209 1869 1882 10.1084/jem.20112738 22927549
45. Conditioned media from macrophages of M1, but not M2 phenotype, inhibit the proliferation of the colon cancer cell lines HT-29 and CACO-2. Engstrom A, Erlandsson A, Delbro D, Wijkander J, Int J Oncol 2014 44 385 392 24296981
46. Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. Suriano F, Santini D, Perrone G, Amato M, Vincenzi B, Tonini G, Muda A, Boggia S, Buscarini M, Pantano F, J Exp Clin Cancer Res 2013 32 87 10.1186/1756-9966-32-87 24423367
47. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Brandau S, Suttmann H, Biomed Pharmacother 2007 61 299 305 10.1016/j.biopha.2007.05.004 17604943
48. Targeting tumor-associated macrophages as a novel strategy against breast cancer. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R, J Clin Invest 2006 116 2132 2141 10.1172/JCI27648 16862213
49. Role of macrophage targeting in the antitumor activity of trabectedin. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van RN, Mortarini R, Beltrame L, Marchini S, Fuso NI, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P, Cancer Cell 2013 23 249 262 10.1016/j.ccr.2013.01.008 23410977
50. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van RN, Weissman IL, Cell 2009 138 286 299 10.1016/j.cell.2009.05.045 19632179
51. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. Grugan KD, McCabe FL, Kinder M, Greenplate AR, Harman BC, Ekert JE, van RN, Anderson GM, Nemeth JA, Strohl WR, Jordan RE, Brezski RJ, J Immunol 2012 189 5457 5466 10.4049/jimmunol.1201889 23105143
52. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, Haas KM, Tedder TF, Blood 2008 112 1205 1213 10.1182/blood-2008-01-135160 18495955
53. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L, J Clin Oncol 2008 26 440 446 10.1200/JCO.2007.12.8298 18086798
54. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH, Science 2011 331 1612 1616 10.1126/science.1198443 21436454